Simple and straight to the source: tips for ileitis control
Simple and straight to the source: tips for ileitis control
Search
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.
Helping patients by addressing health system gaps
Helping patients by addressing health system gaps
Helping patients by addressing health system gaps
Helping patients by addressing health system gaps
Helping patients by addressing health system gaps
Helping patients by addressing health system gaps
Swine
Swine
UBC launches Canada's first graduate blockchain training path
UBC launches Canada's first graduate blockchain training path
Improving primary care in Alberta’s Indigenous Populations
Improving primary care in Alberta’s Indigenous Populations
Innovative health projects impact thousands of Indigenous Peoples in Canada
Innovative health projects impact thousands of Indigenous Peoples in Canada
Using AI to power patient-centric guideline optimization
Using AI to power patient-centric guideline optimization
Improving the lives of Albertans with Progressive Fibrosing Interstitial Lung Disease
Improving the lives of Albertans with Progressive Fibrosing Interstitial Lung Disease
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF study
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER-IPF™ study
R&D - Transforming tomorrow
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it's like working on the cutting edge of pharmaceutical development.
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
Medicine & Regulatory Affairs
Medicine & Regulatory Affairs
Purchasing
Purchasing at Boehringer Ingelheim
Toronto nurse from Princess Margaret Hospital named as the 2019 Oncology Nurse of the Year by the Canadian Association of Nurses in Oncology/Association canadienne des infirmières en oncologie (CANO/ACIO)
Toronto nurse from Princess Margaret Hospital named as the 2019 Oncology Nurse of the Year by the Canadian Association of Nurses in Oncology/Association canadienne des infirmières en oncologie (CANO/ACIO)
Corporate profile
Corporate profile
Patient Centricity
Patient Centricity
Supporting Sustainable Healthcare
Supporting Sustainable Healthcare
Application Platform Data privacy statement
(Application Platform) Data Privacy Statement | Boehringer Ingelheim Careers and Job Opportunities
Our Animal Health story
Our Animal Health story
Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis
New clinical trial data published in the New England Journal of Medicine, showed that spesolimab, a novel IL-36R antibody treatment, was effective in rapidly treating adult patients with generalized pustular psoriasis (GPP) experiencing a flare.
Atrial Fibrillation
Atrial Fibrillation
Inadvertent self-injection: The risk associated with oil-based vaccines
Inadvertent self-injection: The risk associated with oil-based vaccines